DMARDs,biologics,RA
14 March 2023

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Long-Term Survival of Idiopathic Inflammatory Myopathies A single center cohort study analyzed the outcome and surviva

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Long-Term Survival of Idiopathic Inflammatory Myopathies A single center cohort study analyzed the outcome and survival of IIM patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis. https://t.co/EmxRcDCIVn https://t.co/ngtMgrO9Jc
Links
https://bit.ly/3JzJT9h

Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis A multinational study of RA patients shows a variety of pos

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis A multinational study of RA patients shows a variety of post-translationally modified AMPA. While AMPA differed in different ethnic populations, their levels correlated with total serum IgG. https://t.co/QuA980svOO https://t.co/M7706bqxtl
Links
https://bit.ly/3yCiD3T
14 March 2023
Optimal Timing of Elective Hip or Knee Arthroplasty
The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) released a summary of its new guideline titled “The Optimal Timing of Elective Hip or Knee Arthroplasty for Patients with Symptomatic Moderate to Severe Osteoarthritis or Osteonecrosis Who Have Failed Nonoperative Therapy.”

Higher Rehospitalization Rates in Younger SLE Patients A Medicare study shows that young adults with SLE exhibit very

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Higher Rehospitalization Rates in Younger SLE Patients A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients. https://t.co/5KvpgSxhzY https://t.co/6mDPcY0tkS
Links
https://bit.ly/3JggWOB

Metanalysis of adverse PREG outcomes in 1675 women (1920 pregs) w/ anti-SSA/RO Abs - 4% preg termination, 5% spontaneo

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Metanalysis of adverse PREG outcomes in 1675 women (1920 pregs) w/ anti-SSA/RO Abs - 4% preg termination, 5% spontaneous Ab, 26% preterm labor, 50% C-sect, 4% perinatal death, 3% IUGR, 7-12% heart block recurrence, 19% cut. neonatal LE https://t.co/pD2JkMsyVX https://t.co/oiSiwx9Ruj
Links
https://bit.ly/3mRhPoU

QD Clinic - RheumNow Live 2023 Preview

VTE Risks and JAK inhibition

ADD THE FIRST COMMENT

13 March 2023
Carpal Tunnel - Steroid injection vs. Night Splinting

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×